PURPOSE: It has been reported that the sodium/iodide symporter (NIS) gene is expressed in several breast cancer tissues, suggesting the possibility of radionuclide imaging and therapy. However, the regulatory mechanism of NIS gene expression in breast cancer is not yet understood. To assess the relationship between the hormonal status and the NIS expression in breast cancer tissue, we investigated the NIS expression and correlated it to the expression of the thyrotropin receptor (thyroid stimulating hormone receptor, TSH-R), the estrogen receptor (ER) and the progesterone receptor (PR) in human breast cancer tissues. MATERIALS AND METHODS: Breast cancer tissues were obtained from 44 patients. Pathological examination showed 2 cases of Grade I, 17 of Grade II, 22 of Grade III, and 3 of unknown grade. We measured the expression of NIS and TSH-R genes by using RT-PCR and we measured the status of ER and PR by using immunohistochemistry. RESULTS: The NIS gene was expressed in 15 (34%) of the 44 breast cancer tissues. The NIS gene was expressed in 32% of the cases with TSH-R gene expression. The NIS gene was expressed in 40% of the breast cancer tissues with a positive PR and in 31% with a negative PR (p>0.05). It was positive for PR in 18% of the cases and negative for PR in 39% of the cases (p>0.05). CONCLUSION: The NIS gene is expressed in approximately one-third of the human breast cancer tissues. Its expression was not related to the presence of the TSH-R gene or hormonal receptors, ER and PR.
PURPOSE: It has been reported that the sodium/iodide symporter (NIS) gene is expressed in several breast cancer tissues, suggesting the possibility of radionuclide imaging and therapy. However, the regulatory mechanism of NIS gene expression in breast cancer is not yet understood. To assess the relationship between the hormonal status and the NIS expression in breast cancer tissue, we investigated the NIS expression and correlated it to the expression of the thyrotropin receptor (thyroid stimulating hormone receptor, TSH-R), the estrogen receptor (ER) and the progesterone receptor (PR) in humanbreast cancer tissues. MATERIALS AND METHODS:Breast cancer tissues were obtained from 44 patients. Pathological examination showed 2 cases of Grade I, 17 of Grade II, 22 of Grade III, and 3 of unknown grade. We measured the expression of NIS and TSH-R genes by using RT-PCR and we measured the status of ER and PR by using immunohistochemistry. RESULTS: The NIS gene was expressed in 15 (34%) of the 44 breast cancer tissues. The NIS gene was expressed in 32% of the cases with TSH-R gene expression. The NIS gene was expressed in 40% of the breast cancer tissues with a positive PR and in 31% with a negative PR (p>0.05). It was positive for PR in 18% of the cases and negative for PR in 39% of the cases (p>0.05). CONCLUSION: The NIS gene is expressed in approximately one-third of the humanbreast cancer tissues. Its expression was not related to the presence of the TSH-R gene or hormonal receptors, ER and PR.
Authors: P P Smyth; D F Smith; E W McDermott; M J Murray; J G Geraghty; N J O'Higgins Journal: J Clin Endocrinol Metab Date: 1996-03 Impact factor: 5.958
Authors: Irene L Wapnir; Matt van de Rijn; Kent Nowels; Peter S Amenta; Kelly Walton; Kelli Montgomery; Ralph S Greco; Orsolya Dohán; Nancy Carrasco Journal: J Clin Endocrinol Metab Date: 2003-04 Impact factor: 5.958
Authors: M P Postiglione; R Parlato; A Rodriguez-Mallon; A Rosica; P Mithbaokar; M Maresca; R C Marians; T F Davies; M S Zannini; M De Felice; R Di Lauro Journal: Proc Natl Acad Sci U S A Date: 2002-11-13 Impact factor: 11.205
Authors: Orsolya Dohán; Antonio De la Vieja; Viktoriya Paroder; Claudia Riedel; Mona Artani; Mia Reed; Christopher S Ginter; Nancy Carrasco Journal: Endocr Rev Date: 2003-02 Impact factor: 19.871
Authors: P A Smanik; Q Liu; T L Furminger; K Ryu; S Xing; E L Mazzaferri; S M Jhiang Journal: Biochem Biophys Res Commun Date: 1996-09-13 Impact factor: 3.575
Authors: Geeta Upadhyay; Rajesh Singh; Gaurav Agarwal; Saroj K Mishra; Lily Pal; Prasanta K Pradhan; Birendra K Das; Madan M Godbole Journal: Breast Cancer Res Treat Date: 2003-01 Impact factor: 4.872
Authors: Markus Luster; Steven I Sherman; Monica C Skarulis; James R Reynolds; Michael Lassmann; Heribert Hänscheid; Christoph Reiners Journal: Eur J Nucl Med Mol Imaging Date: 2003-07-15 Impact factor: 9.236
Authors: Sasha J Beyer; Xiaoli Zhang; Rafael E Jimenez; Mei-Ling T Lee; Andrea L Richardson; Kun Huang; Sissy M Jhiang Journal: BMC Res Notes Date: 2011-10-11
Authors: Chang Min Park; Young Don Lee; Eun Mee Oh; Kwan-Il Kim; Heung Kyu Park; Kwang-Pil Ko; Yoo Seung Chung Journal: Ann Surg Treat Res Date: 2014-03-25 Impact factor: 1.859
Authors: Katarzyna D Arczewska; Marlena Godlewska; Wanda Krasuska; Anna Łyczkowska; Mirosław Kiedrowski; Barbara Czarnocka Journal: Arch Med Sci Date: 2019-11-25 Impact factor: 3.707
Authors: Fatma Umit Malya; Huseyin Kadioglu; Mustafa Hasbahceci; Kemal Dolay; Mehmet Guzel; Yeliz Emine Ersoy Journal: J Int Med Res Date: 2017-08-31 Impact factor: 1.671